Soleno Therapeutics, Inc.
SLNO
$52.95
$0.020.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 285.01M | 190.41M | 98.68M | 32.66M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 285.01M | 190.41M | 98.68M | 32.66M | -- |
| Cost of Revenue | 3.90M | 2.70M | 1.84M | 696.00K | -- |
| Gross Profit | 281.11M | 187.71M | 96.84M | 31.96M | -- |
| SG&A Expenses | 153.24M | 132.13M | 128.55M | 144.00M | 126.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 195.52M | 175.46M | 182.95M | 218.98M | 204.13M |
| Operating Income | 89.49M | 14.95M | -84.27M | -186.32M | -204.13M |
| Income Before Tax | 99.58M | 20.89M | -78.45M | -181.08M | -198.23M |
| Income Tax Expenses | 3.54M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.04 | 20.89 | -78.45 | -181.08 | -198.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.04M | 20.89M | -78.45M | -181.08M | -198.23M |
| EBIT | 89.49M | 14.95M | -84.27M | -186.32M | -204.13M |
| EBITDA | 91.52M | 16.97M | -82.26M | -184.32M | -202.13M |
| EPS Basic | 1.80 | 0.25 | -1.83 | -4.15 | -4.62 |
| Normalized Basic EPS | 1.21 | 0.23 | -1.08 | -2.52 | -2.80 |
| EPS Diluted | 1.76 | 0.22 | -1.85 | -4.15 | -4.62 |
| Normalized Diluted EPS | 1.18 | 0.21 | -1.09 | -2.52 | -2.80 |
| Average Basic Shares Outstanding | 209.08M | 203.17M | 193.92M | 182.47M | 170.61M |
| Average Diluted Shares Outstanding | 212.80M | 205.92M | 195.51M | 182.47M | 170.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |